Table 2.
Correlations between the changes in non-motor symptoms (NMSS total score and NMSS domains) and other disease-related variables in PD patients from V0 (baseline) to V2 (2 years ± 1 month).
| NMSS TS |
NMSS D1 |
NMSS D2 |
NMSS D3 |
NMSS D4 |
NMSS D5 |
NMSS D6 |
NMSS D7 |
NMSS D8 |
NMSS D9 |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Age at baseline | −0.06 | 0.12 *** | −0.03 | −0.01 | 0.04 | 0.04 | −0.04 | −0.08 | −0.03 | −0.04 |
| Disease duration (at V0) | 0.10 *** | 0.11 *** | 0.02 | 0.07 | 0.06 | 0.04 | 0.02 | 0.06 | 0.12 *** | 0.05 |
| N. of non-antipark. drugs (at V0) | −0.05 | 0.12 *** | −0.03 | −0.03 | 0 | −0.02 | −0.03 | −0.06 | −0.02 | −0.07 |
| Change at V2 (from V0 to V2) | ||||||||||
| LEDD | 0.02 | −0.02 | 0.03 | 0.02 | 0.02 | 0.01 | 0.08 | 0.04 | −0.01 | 0 |
| Daily dose L-dopa (mg) | 0.01 | −0.05 | 0.01 | 0.03 | −0.02 | 0.02 | 0.05 | 0.01 | −0.03 | 0.04 |
| Equivalent daily dose of DA (mg) | −0.04 | 0.02 | 0.02 | −0.1 | 0.02 | −0.09 *** | 0.05 | −0.04 | −0.06 | −0.05 |
| Number of non-antipark. drugs | 0.06 | 0.07 | −0.02 | 0 | 0.09 *** | 0.08 | 0.03 | 0.07 | 0 | 0.04 |
| UPDRS-III (OFF) | 0.16 * | 0.07 | 0.12 *** | 0.16 ** | 0.07 | 0.11 *** | 0.07 | 0.14 *** | 0 | 0.15 *** |
| UPDRS-IV | 0.10 *** | 0.02 | 0.12 *** | 0.09 | 0.06 | 0 | 0.06 | 0.11 *** | 0 | 0.04 |
| FOGQ | 0.21 * | 0.11 *** | 0.19 * | 0.13 ** | 0.09 *** | 0.13 *** | 0.12 *** | 0.14 *** | 0.10 *** | 0.11 *** |
| PD-CRS | 0.01 | −0.05 | −0.04 | −0.01 | −0.05 | −0.11 *** | 0.02 | −0.03 | 0.15 | 0.03 |
| BDI-II | 0.35 * | 0.17 * | 0.29 * | 0.33 * | 0.19 * | 0.22 * | 0.09 *** | 0.15 ** | 0.13 *** | 0.14 *** |
| PDSS | −0.34 * | −0.04 | −0.34 * | −0.23 | −014 ** | −0.15 ** | −0.17* | −0.24 * | −0.12 *** | −0.17 * |
| QUIP-RS | 0.10 *** | 0 | 0.06 | −0.03 | 0.17 * | 0.05 | −0.02 | 0.11 *** | 0.03 | 0.05 |
| NPI | 0.31 * | 0.12 *** | 0.19 * | −0.03 | 0.21 * | 0.18 * | 0.12 *** | 0.12 *** | 0.14 *** | 0.06 |
| VAS-PAIN | 0.12 *** | 0.09 *** | 0.09 *** | 0.41 * | 0.06 | 0.01 | 0.07 | 0.02 | 0.11 *** | 0.12 *** |
| VASF-physical | 0.21 * | 0.01 | 0.10 *** | 0.11 *** | 0.07 | 0.08 | 0.13 *** | 0.08 | 0.09 | 0.14 *** |
| VASF-mental | 0.21 * | 0 | 0.15 * | 0.18 * | 0.07 | 0.11 | 0.18 * | 0.09 | 0.07 | 0.10 *** |
| PDQ-39SI | 0.42 * | 0.09 *** | 0.33 * | 0.35 * | 0.15 ** | 0.23 * | 0.20 * | 0.19 *** | 0.12 *** | 0.17 * |
| PQ-10 | −0.17 * | −0.06 | −0.15 ** | −0.17 * | −0.11 *** | −0.11 *** | −0.07 | −0.07 | −0.01 | −0.08 |
| EUROHIS-QOL8 | −0.20 * | −0.03 | −0.25 * | −0.09 *** | −0.11 *** | −0.12 *** | −0.05 | −013 *** | −0.04 | −0.09 |
| ADLS | −0.24 * | −0.35 * | −0.19 * | −0.19 | −0.15 ** | −0.18 * | −0.17 | −0.15 ** | −0.17 * | −0.10 *** |
Spearman correlation test was applied. *, p < 0.0001; **, p < 0.001; ***, p < 0.05. In bold are expressed significant values. NMSS: TS, total score. D1, Cardiovascular (items 1 and 2; score, 0 to 24); D2, Sleep/fatigue (items 3, 4, 5, and 6; score, 0 to 48); D3, Depression/apathy (items 7, 8, 9, 10, 11, and 12; score, 0 to 72); D4, Perceptual problems/hallucinations (items 13, 14, and 15; score, 0 to 36); D5, Attention/memory (items 16, 17, and 18; score, 0 to 36); D6, Gastrointestinal tract (items 19, 20, and 21; score 0 to 36); D7, Urinary symptoms (items 22, 23, and 24; score, 0 to 36); D8, Sexual dysfunction (items 25 and 26; score 0 to 24); D9, Miscellaneous (items 27, 28, 29, and 30; score, 0 to 48). ADLS, Schwab & England Activities of Daily Living Scale; BDI-II, Beck Depression Inventory-II; DA, dopamine agonist; FOGQ, Freezing Of Gait Questionnaire; LEDD, levodopa equivalent dauly dose; N, number; NMSS, Non-Motor Symptoms Scale; NPI, Neuropsychiatric Inventory; PD-CRS, Parkinson’s Disease Cognitive Rating Scale; PDSS, Parkinson’s Disease Sleep Scale; QUIP-RS, Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale; TS, total score; UPDRS, Unified Parkinson’s Disease Rating Scale; VAFS, Visual Analog Fatigue Scale; VAS-Pain, Visual Analog Scale-Pain.